Year in Review
In a year of unprecedented hardship we witnessed never-before-seen speeds of innovation and levels of collaboration in the global healthcare community.
As we reflect on the past year, we are proud to share highlights from our team and portfolio who responded, contributed, and innovated throughout it all.
Initiated world’s first controlled clinical trial for a CRISPR-enhanced bacteriophage therapy
Granted FDA clearance for atrial fibrillation and heart murmur AI algorithms for use with its digital stethoscopes
Excision's technology inventor, Jennifer Doudna, wins 2020 Nobel Prize in Chemistry
Helped more than 165,000 patients get access to on-demand virtual care
Executed one of the year's most successful direct listings on NASDAQ (PLTR: Mkt Cap $54B)
Demonstrated high sensitivity and specificity in multiomics blood test for detecting early-stage colorectal cancer
Reached a major R&D breakthrough with the discovery of a subset of plant-derived proteins that work comparably to collagen, enabling the team to scale production
Reached space with Rocket 3.2, its second launch attempt
New Companies Joined Our Portfolio
Including incubation and launch of 3 startups
New Funding Rounds
Second Front: Seed